TrialClinical pharmacology in drug development2021

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.

Ramesh Boinpally et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.